Literature DB >> 26272232

Clopidogrel and CYP2C19: pharmacogenetic testing ready for clinical prime time?

Michael J Knauer1, Eleftherios P Diamandis2, Jean-Sebastien Hulot3, Richard B Kim4, Derek Y F So5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26272232     DOI： 10.1373/clinchem.2015.238105

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  3 in total

1.  Comparison of a rapid point-of-care and two laboratory-based CYP2C19*2 genotyping assays for personalisation of antiplatelet therapy.

Authors:  Francesca Wirth; Graziella Zahra; Robert G Xuereb; Christopher Barbara; Albert Fenech; Lilian M Azzopardi
Journal:  Int J Clin Pharm       Date:  2016-03-15

2.  Analytical validation of GMEX rapid point-of-care CYP2C19 genotyping system for the CHANCE-2 trial.

Authors:  Xia Meng; Anxin Wang; Guojun Zhang; Siying Niu; Wei Li; Sifei Han; Fang Fang; Xingquan Zhao; Kehui Dong; Zening Jin; Huaguang Zheng; Kelin Chen; Hao Li; Chengyuan Yang; Yongjun Wang
Journal:  Stroke Vasc Neurol       Date:  2021-05-05

3.  Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application.

Authors:  J T Oates; D Lopez
Journal:  Int J Biomed Investig       Date:  2018-05-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.